<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation using an HLA-MLC-identical sibling is the most valuable treatment of severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>.2,6,7 Between November 1973 and March 1977, 25 consecutive patients have been treated by marrow transplantation in our unit </plain></SENT>
<SENT sid="1" pm="."><plain>Nine patients are alive with complete hematologic restoration between 3 months and 3 years </plain></SENT>
<SENT sid="2" pm="."><plain>The high mortality can be largely accounted for by marrow graft rejection (14 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Despite the small number of patients, we have tried to identify prognostic factors associated with marrow graft rejection </plain></SENT>
<SENT sid="4" pm="."><plain>They are mainly the existence of anti-HLA antibodies, the sex difference, and the <z:mpath ids='MPATH_458'>normal</z:mpath> PHA and MLC response before grafting </plain></SENT>
<SENT sid="5" pm="."><plain>After the graft, the disappearance of anti-HLA antibodies has a good prognostic value </plain></SENT>
<SENT sid="6" pm="."><plain>The appearance of autolymphocytotoxins seems to correlate strongly either with rejection or <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
</text></document>